Emmanuelle L. Waubant

MD PhD

Director, Regional Pediatric Multiple Sclerosis Center
Neurologist
International expert on pediatric and adult MS

Dr. Emmanuelle L. Waubant is a neurologist who specializes in treating patients with multiple sclerosis (MS). She serves as director of the UCSF Regional Pediatric Multiple Sclerosis Center.

Waubant's research focuses on new treatments for MS. She also studies environmental and genetic risk factors, including in children with the disease.

A native of France, Waubant earned her medical degree at the Lille University School of Medicine and completed a residency in neurology at Toulouse University Hospital, where she was chief resident as well as junior faculty for two years. She completed fellowships in neuroimmunology and clinical neuroimmunology at UCSF and then returned to her native country to head a clinical research center at the Pitié-Salpêtrière University Hospital in Paris. She joined the UCSF Multiple Sclerosis Center in 2001.

Waubant serves on the clinical care committee of the National Multiple Sclerosis Society's local chapter and on the translational research review committee for the society's national office. She chairs the clinical trial task force and serves on the steering committee of the International Pediatric Multiple Sclerosis Study Group.

A prominent contributor to scientific journals in her field, Waubant is one of two chief editors of Multiple Sclerosis and Related Disorders, and she is MS section editor for Annals of Clinical and Translational Neurology.

Waubant speaks French.

  • Education

    Lille University School of Medicine, 1992

  • Residencies

    Toulouse University Hospital, Neurology, 1992

  • Fellowships

    UCSF Medical Center, Neurology, 1999

  • Academic Title

    Professor

  • Languages

    French

I care for patients with MS, lead research seeking to advance therapies and mentor junior investigators who will be tomorrow's stars in the field.

Multiple Sclerosis Center

1500 Owens St., Suite 320
San Francisco, CA 94158

Decorative Caduceus

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there i...

Recruiting

Share